|
WO2021061066A1
|
|
Effervescent formulations of sapropterin dihydrochloride
|
|
WO2021045706A1
|
|
A combination comprising vildagliptin and metformin
|
|
WO2021054912A1
|
|
Effervescent tablet formulations comprising dapagliflozin and metformin
|
|
WO2021061067A1
|
|
Pharmaceutical formulations comprising sapropterin dihydrochloride and at least one antioxidant
|
|
WO2021061065A1
|
|
Solid oral pharmaceutical formulations comprising sapropterin dihydrochloride and at least one pharmaceutical excipient
|
|
WO2021010924A1
|
|
An effervescent tablet composition of sitagliptin
|
|
WO2020112060A1
|
|
A composition comprising dimethyl fumarate
|
|
WO2020112059A2
|
|
The delayed release capsule comprising dimethyl fumarate
|
|
WO2020122839A2
|
|
A combination comprising a multiple sclerosis agent and at least one muscle relaxant agent
|
|
WO2020122838A2
|
|
A combination comprising a multiple sclerosis agent and at least one anti-epileptic agent
|
|
WO2020117161A1
|
|
A combination comprising dimethyl fumarate and at least one muscle relaxant agent
|
|
WO2020086046A2
|
|
Topical compositions comprising tolperisone and flurbiprofen combination
|
|
WO2020086038A2
|
|
Topical compositions comprising tolperisone and selective cox-2 inhibitor combination
|
|
TR201912004A2
|
|
A SAFE FORMULATION CONTAINING POLYETHYLENE GLYCOL
|
|
WO2020055364A2
|
|
A pharmaceutical composition comprising eltrombopag olamine
|
|
WO2020005189A2
|
|
Solid oral pharmaceutical compositions comprising teriflunomide
|
|
EP3810112A2
|
|
A combination comprising fingolimod and modafinil
|
|
WO2019245513A2
|
|
A combination comprising fingolimod and amantadine
|
|
EP3810274A2
|
|
A combination comprising fingolimod and at least one anti-epileptic agent
|
|
TR201908440A2
|
|
APREMİLASTIN TABLET FORMULATIONS
|
